Ronald L. Veselenak

Mutations Conferring Resistance to SCH6, a Novel Hepatitis C Virus NS3/4A Protease Inhibitor

MinKyung Yi, Xiao Tong, Angela Skelton et al. · Journal of Biological Chemistry · 2005 · 104 citations · Full text

Life Sciences, Genetics, Molecular Biology +17

The Fibroblast Growth Factor 14·Voltage-gated Sodium Channel Complex Is a New Target of Glycogen Synthase Kinase 3 (GSK3)

Alexander S. Shavkunov, Norelle C. Wildburger, Miroslav N. Nenov et al. · Journal of Biological Chemistry · 2013 · 88 citations · Full text

Life Sciences, Biochemistry, Molecular Biology +14

A Vaxfectin®-adjuvanted HSV-2 plasmid DNA vaccine is effective for prophylactic and therapeutic use in the guinea pig model of genital herpes

Ronald L. Veselenak, Mark Shlapobersky, Richard B. Pyles et al. · Vaccine · 2012 · 59 citations

Veterinary Medicine, Immunology, Infectious Diseases +17

Activity and the metabolic activation pathway of the potent and selective hepatitis C virus pronucleotide inhibitor PSI-353661

Phillip A. Furman, Eisuke Murakami, Congrong Niu et al. · Antiviral Research · 2011 · 47 citations

Life Sciences, Biochemistry, Medicinal Chemistry +10

Inhibition of Hepatitis C Virus Replicon RNA Synthesis by PSI-352938, a Cyclic Phosphate Prodrug of β-<scp>d</scp>-2′-Deoxy-2′-α-Fluoro-2′-β-<i>C</i>-Methylguanosine

Angela M. Lam, Christine Espiritu, Eisuke Murakami et al. · Antimicrobial Agents and Chemotherapy · 2011 · 39 citations · Full text

Medicine, Medicinal Chemistry, Pharmacology +17